[
  {
    "ts": "2025-06-23T13:53:00+00:00",
    "headline": "FDA Extends INCY's Application for Opzelura Label Expansion",
    "summary": "FDA extends review of Incyte's ruxolitinib cream for children with atopic dermatitis, delaying decision to September 2025.",
    "url": "https://finance.yahoo.com/news/fda-extends-incys-application-opzelura-135300321.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "d232c0a5-7f6e-386d-bb28-ae481c4898ba",
      "content": {
        "id": "d232c0a5-7f6e-386d-bb28-ae481c4898ba",
        "contentType": "STORY",
        "title": "FDA Extends INCY's Application for Opzelura Label Expansion",
        "description": "",
        "summary": "FDA extends review of Incyte's ruxolitinib cream for children with atopic dermatitis, delaying decision to September 2025.",
        "pubDate": "2025-06-23T13:53:00Z",
        "displayTime": "2025-06-23T13:53:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Z6CaNjdpI8OLeo5.Ul_eA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o6kyOwY40meLORq99yf8XA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fda-extends-incys-application-opzelura-135300321.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-extends-incys-application-opzelura-135300321.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            },
            {
              "symbol": "BAYN.DE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-06-23T04:19:33+00:00",
    "headline": "5 Revealing Analyst Questions From Incyte’s Q1 Earnings Call",
    "summary": "Incyte’s first quarter was marked by significant commercial momentum and robust top-line growth, leading to a positive market reaction. Management attributed the results to strong demand for Jakafi and Opselura, the initial sales contribution from recently launched Niktimvo, and continued expansion in dermatology and hematology-oncology portfolios. CEO Herve Hoppenot emphasized that “Q1 2025 puts us on a great trajectory for long-term growth with the continuous expansion of Apteloa, successful l",
    "url": "https://finance.yahoo.com/news/5-revealing-analyst-questions-incyte-041933328.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "a710a2d7-1668-37bd-9502-95bd169da62c",
      "content": {
        "id": "a710a2d7-1668-37bd-9502-95bd169da62c",
        "contentType": "STORY",
        "title": "5 Revealing Analyst Questions From Incyte’s Q1 Earnings Call",
        "description": "",
        "summary": "Incyte’s first quarter was marked by significant commercial momentum and robust top-line growth, leading to a positive market reaction. Management attributed the results to strong demand for Jakafi and Opselura, the initial sales contribution from recently launched Niktimvo, and continued expansion in dermatology and hematology-oncology portfolios. CEO Herve Hoppenot emphasized that “Q1 2025 puts us on a great trajectory for long-term growth with the continuous expansion of Apteloa, successful l",
        "pubDate": "2025-06-23T04:19:33Z",
        "displayTime": "2025-06-23T04:19:33Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/dd5ed23043756cdda4b65d5c228863e0",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "INCY Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9ebFa.LFGXWDaOAygGvuNg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/dd5ed23043756cdda4b65d5c228863e0.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ojCguUNIH7INClq6_Rac1A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/dd5ed23043756cdda4b65d5c228863e0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/5-revealing-analyst-questions-incyte-041933328.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/5-revealing-analyst-questions-incyte-041933328.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-06-23T03:31:41+00:00",
    "headline": "Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks",
    "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Regeneron (NASDAQ:REGN) and its peers.",
    "url": "https://finance.yahoo.com/news/q1-rundown-regeneron-nasdaq-regn-033141632.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "af9fbfcd-3bfd-3273-b418-af2a88f47586",
      "content": {
        "id": "af9fbfcd-3bfd-3273-b418-af2a88f47586",
        "contentType": "STORY",
        "title": "Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks",
        "description": "",
        "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Regeneron (NASDAQ:REGN) and its peers.",
        "pubDate": "2025-06-23T03:31:41Z",
        "displayTime": "2025-06-23T03:31:41Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "REGN Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/E5YeVaDzgHlFxvDwMx9gpg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6HLp77Q1Eazwpb8zaGf6Xg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/q1-rundown-regeneron-nasdaq-regn-033141632.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/q1-rundown-regeneron-nasdaq-regn-033141632.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            },
            {
              "symbol": "NTRA"
            },
            {
              "symbol": "EXAS"
            },
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]